Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | DNTT | P04053 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10918418 | 0.71 | CYP1A2 (0.37) | CYP1A2HIF1AALDH1A1TSHRMAPT | |
| SCHEMBL18552682 | 0.68 | — | — | |
| SCHEMBL14490713 | 0.67 | ALDH1A1 (0.38) | CYP1A2ALDH1A1HTTATMKMT2A | |
| SCHEMBL14193665 | 0.67 | ALDH1A1 (0.38) | CYP1A2ALDH1A1HTTATMKMT2A | |
| SCHEMBL14827588 | 0.66 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PKMHTTKMT2A | |
| SCHEMBL18461270 | 0.66 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PKMHTTKMT2A | |
| SCHEMBL7197213 | 0.66 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PKMHTTKMT2A | |
| SCHEMBL147771 | 0.66 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PKMHTTKMT2A | |
| SCHEMBL5732376 | 0.66 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PKMHTTKMT2A | |
| SCHEMBL30363373 | 0.66 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PKMHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676471-B2 | Cycloalkyl-linked diheterocycle derivatives | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3556757-A1 | CYCLOALKYL-LINKED DIHETEROCYCLE DERIVATIVES | Pfizer Inc (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3137460-B1 | CYCLOALKYL-LINKED DIHETEROCYCLE DERIVATIVES | PFIZER (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190270737-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190040055-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | PFIZER INC. (US) | 2019-02-07 | — | — | US | disclosed |
| US-10125130-B2 | Cycloalkyl-linked diheterocycle derivatives | PFIZER INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180148441-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148441-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| EP-3137460-A1 | CYCLOALKYL-LINKED DIHETEROCYCLE DERIVATIVES | Pfizer Inc. (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20170050958-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | PFIZER INC. (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170050958-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | PFIZER INC. (US) | 2017-02-23 | — | — | US | disclosed |
| WO-2015166373-A1 | CYCLOALKYL-LINKED DIHETEROCYCLE DERIVATIVES | PFIZER INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015166373-A1 | CYCLOALKYL-LINKED DIHETEROCYCLE DERIVATIVES | PFIZER INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-8822480-B2 | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators | MERCK SHARP & DOHME CORP. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815876-B2 | Bicyclic heterocycle derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110166165-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | SCHERING CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166167-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166165-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | GPR119, GPR88, GCGR | CYP1A2 789/4885HIF1A 601/4885ALDH1A1 1551/4885 |
| US-20180148441-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | CCNY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCND2 | CYP1A2 1768/4885HIF1A 3052/4885ALDH1A1 2190/4885 |
| US-20110166167-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GLP1R | CYP1A2 697/4885HIF1A 764/4885ALDH1A1 1749/4885 |
| US-10125130-B2 | Cycloalkyl-linked diheterocycle derivatives | CCNY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCND2 | CYP1A2 1768/4885HIF1A 3052/4885ALDH1A1 2190/4885 |
| US-20190270737-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | CCNY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCND2 | CYP1A2 1768/4885HIF1A 3052/4885ALDH1A1 2190/4885 |
| US-10676471-B2 | Cycloalkyl-linked diheterocycle derivatives | CCNY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCND2 | CYP1A2 1768/4885HIF1A 3052/4885ALDH1A1 2190/4885 |
| US-20170050958-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | CCNY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCND2 | CYP1A2 1768/4885HIF1A 3052/4885ALDH1A1 2190/4885 |
| US-20190040055-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | CCNY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCND2 | CYP1A2 1768/4885HIF1A 3052/4885ALDH1A1 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.